- Home
- RPTX vs HOWL Comparison
RPTX vs HOWL Comparison
Compare RPTX & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPTX
- HOWL
- Stock Information
- Founded
- RPTX 2016
- HOWL 2017
- Country
- RPTX Canada
- HOWL United States
- Employees
- RPTX N/A
- HOWL N/A
- Industry
- RPTX Biotechnology: Pharmaceutical Preparations
- HOWL Biotechnology: Pharmaceutical Preparations
- Sector
- RPTX Health Care
- HOWL Health Care
- Exchange
- RPTX Nasdaq
- HOWL Nasdaq
- Market Cap
- RPTX 63.9M
- HOWL 53.8M
- IPO Year
- RPTX 2020
- HOWL 2021
- Fundamental
- Price
- RPTX $1.41
- HOWL $1.21
- Analyst Decision
- RPTX Strong Buy
- HOWL Strong Buy
- Analyst Count
- RPTX 3
- HOWL 3
- Target Price
- RPTX $4.50
- HOWL $8.33
- AVG Volume (30 Days)
- RPTX 92.3K
- HOWL 485.3K
- Earning Date
- RPTX 08-05-2025
- HOWL 08-07-2025
- Dividend Yield
- RPTX N/A
- HOWL N/A
- EPS Growth
- RPTX N/A
- HOWL N/A
- EPS
- RPTX N/A
- HOWL N/A
- Revenue
- RPTX $1,073,000.00
- HOWL $1,143,000.00
- Revenue This Year
- RPTX N/A
- HOWL N/A
- Revenue Next Year
- RPTX N/A
- HOWL N/A
- P/E Ratio
- RPTX N/A
- HOWL N/A
- Revenue Growth
- RPTX N/A
- HOWL N/A
- 52 Week Low
- RPTX $0.89
- HOWL $0.60
- 52 Week High
- RPTX $4.29
- HOWL $4.18
- Technical
- Relative Strength Index (RSI)
- RPTX 51.83
- HOWL 51.44
- Support Level
- RPTX $1.33
- HOWL $1.19
- Resistance Level
- RPTX $1.48
- HOWL $1.35
- Average True Range (ATR)
- RPTX 0.05
- HOWL 0.13
- MACD
- RPTX -0.01
- HOWL -0.02
- Stochastic Oscillator
- RPTX 34.37
- HOWL 21.84
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.